Comparison · NCT03186209-c1853914
Benralizumab 30 mg vs Placebo: Number and Percentage of Patients With >=1 Asthma Exacerbations Among Patients Who Were on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Benralizumab 30 mg vs Placebo: Number and Percentage of Patients With >=1 Asthma Exacerbations Among Patients Who Were on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL. Trial comparisons, record NCT03186209-c1853914. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03186209-c1853914
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.233 | 0.184 | 0.291 | wilson | |
| Risk in group 2 | 0.527 | 0.464 | 0.59 | wilson | |
| Risk difference, group 1 minus group 2 | -0.294 | -0.374 | -0.208 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.442 | 0.34 | 0.574 | log | |
| Odds ratio, group 1 over group 2 | 0.272 | 0.183 | 0.404 | log | |
| Number needed to treat, for one fewer participant with the outcome on Benralizumab 30 mg than on Placebo | 3.4 | 2.67 | 4.8 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Benralizumab 30 mg | Benralizumab administered subcutaneously | 55 | 236 | OG000 |
| Group 2 | Placebo | Placebo administered subcutaneously | 125 | 237 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number and Percentage of Patients With >=1 Asthma Exacerbations Among Patients Who Were on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL
- Description
- Number and percentage of patients with at least one exacerbation over 48-week treatment period
- Time frame
- From randomization through Study Week 48
- Population
- Full analysis set, Baseline eosinophils \>=300/uL
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
- NCT number
- NCT03186209
- Phases
- PHASE3
- Conditions
- Asthma
- Interventions
- Benralizumab, Placebo
- Lead sponsor
- AstraZeneca
- Results first posted
- 2024-04-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03186209?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03186209-c1853914